ODC1 and pancreatic neoplasm: ODC inhibitor DFMO [62] has been shown to suppress the pancreatic cancer progression by modulating ODC signaling, altering Wnt signaling, decreasing proliferation, and increasing cell cycle arrest markers p53 and p21 [61].